Middle East Journal of Cancer

Current Issue

By Issue

By Author

By Subject

Author Index

Keyword Index

About Journal

Aims and Scope

Editorial Board

Publication Ethics

Indexing and Abstracting

Related Links

FAQ

Peer Review Process

News

Forms

Journal Metrics

Integrated in Silico Analysis Reveals miR-551b-3p as a Potential Tumor Suppressor and Prognostic Biomarker in Breast Cancer

Articles in Press

Document Type : Original Article(s)

Authors

1 Department of Food Engineering, Graduate School of Natural and Applied Sciences, Kahramanmaraş Sütcü Imam University, Kahramanmaraş, Turkey

2 Department of Bioengineering and Sciences, Graduate School of Natural and Applied Sciences, Kahramanmaraş Sütçü İmam University, Kahramanmaraş, Turkey TURKEY

10.30476/mejc.2026.110333.2395

Abstract

Background: Tumor progression in breast cancer is largely driven by microRNA-mediated post-transcriptional regulatory networks; however, the biological and clinical roles of miR-551b-3p remain insufficiently defined. The present study aimed to characterize the expression profile, molecular interactions, and prognostic relevance of miR-551b-3p in breast cancer via in silico analyses.
Method: Designed as an in silico bioinformatic analysis, weassessed miR-551b-3p expression and clinical correlations using the University of Alabama at Birmingham Cancer data analysis portal (UALCAN) and OncomiR. Associated transcription factors were retrieved from TransmiR v3.0, functional enrichment was performed using the Protein Analysis Through Evolutionary Relationships suite, and survival outcomes were evaluated using Kaplan–Meier Plotter. Statistical significance was evaluated via UALCAN, OncomiR, and KM-Plotter using t-tests, ANOVA, and log-rank tests, with the threshold set at P < 0.05.
Results: Our analyses revealed a significant downregulation of miR-551b-3p in breast tumor tissues (log-fold change [log-FC] = -1.1, P < 0.0001). TEAD1, protein tyrosine kinase 2, SMG1, TIMELESS, SLC5A3, and NUP93 emerged as strong target genes, implicating key pathways involved in proliferation, DNA damage response, and metastatic progression. Furthermore, central transcription factors such as E2F1, ESR1, FOXA1, CBX3, and RAD21 were associated with reduced miR-551b-3p expression. In silico screening identified lncRNAs AC069281.2/AL359258.1 and USP9X/TMEM2-derived circRNAs as potential target-directed microRNA degradation (TDMD) candidates Clinically, miR-551b-3p downregulation associated with metastasis and unfavorable survival, serving as a supplementary molecular indicator.
Conclusion: Collectively, these findings support miR-551b-3p as a potential tumor suppressor and prognostic biomarker in breast cancer, warranting further experimental validation.

Keywords

Main Subjects

Please cite this article as: Çelenk KSE, Çakmak S. Integrated in Silico Analysis Reveals miR-551b-3p as a Potential Tumor Suppressor and Prognostic Biomarker in Breast Cancer. Middle East J Cancer. 2026: in press. doi: 10.30476/mejc.2026.110333.2395.

References
  1. Dvir K, Giordano S, Leone JP. Immunotherapy in breast cancer. Int J Mol Sci. 2024;25(14):7517. doi: 10.3390/ijms25147517. PMID: 39062758; PMCID: PMC11276856.
  2. Davey MG, Davies M, Lowery AJ, Miller N, Kerin MJ. The role of MicroRNA as clinical biomarkers for breast cancer surgery and treatment. Int J Mol Sci. 2021;22(15):8290. doi: 10.3390/ijms22158290. PMID: 34361056; PMCID: PMC8346977.
  3. Grimaldi AM, Salvatore M, Incoronato M. miRNA-based therapeutics in breast cancer: A systematic review. Front Oncol. 2021;11:668464. doi: 10.3389/fonc.2021.668464. PMID: 34026646; PMCID: PMC8131824.
  4. Ismail A, El-Mahdy HA, Abulsoud AI, Sallam AM, Eldeib MG, Elsakka EGE, et al. Beneficial and detrimental aspects of miRNAs as chief players in breast cancer: A comprehensive review. Int J Biol Macromol. 2023;224:1541-65. doi: 10.1016/j.ijbiomac.2022.10.241. PMID: 36328268.
  5. Çakmak E. Computational and experimental tools of miRNAs in cancer. Middle East J Cancer. 2020;11(4):381-9. doi: 10.30476/mejc.2020.82239.1069.
  6. Jordan-Alejandre E, Campos-Parra AD, Castro-Lopez DL, Silva-Cazares MB. Potential miRNA use as a biomarker: from breast cancer diagnosis to metastasis. Cells. 2023;12(4):525. doi: 10.3390/cells12040525. PMID: 36831192; PMCID: PMC9954167.
  7. Ghanbari M, Karari K, Altalebi SAR, Majeed SA, Haghi M. The role of MicroRNAs in breast cancer: diagnostic and therapeutic implications. Int J Biol Macromol. 2025;146386. doi: 10.1016/j.ijbiomac.2025.146386. PMID: 40744188.
  8. Parashar D, Geethadevi A, Aure MR, Mishra J, George J, Chen C, et al. miRNA551b-3p activates an oncostatin signaling module for the progression of triple-negative breast cancer. Cell Rep. 2019;29(13):4389–406. doi: 10.1016/j.celrep.2019.11.085. PMID: 31875548; PMCID: PMC7380555.
  9. Wang X, Cheng Z, Dai L, Jiang T, Li P, Jia L, et al. LncRNA PVT1 facilitates proliferation, migration and invasion of NSCLC cells via miR-551b/FGFR1 axis. Onco Targets Ther. 2021;14:3555–65. doi: 10.2147/OTT.S273794. PMID: 34113122; PMCID: PMC8180410.
  10. Çakmak E, Çelik İS. Diagnostic potential of miR-551b-3p in lung cancer: in vitro and in silico experiments. Celal Bayar Univ J Sci. 2025;21(2):125–33. doi: 10.18466/cbayarfbe.1582834.
  11. Yuan H, Chen Z, Bai S, Wei H, Wang Y, Ji R, et al. Molecular mechanisms of lncRNA SMARCC2/miR-551b-3p/TMPRSS4 axis in gastric cancer. Cancer Lett. 2018;418(1):84-96. doi: 10.1016/j.canlet.2018.01.032. PMID: 29337109.
  12. Karanam NK, Ding L, Vo DT, Giri U, Yordy JS, Story MD. miR-551a and miR-551b-3p target GLIPR2 and promote tumor growth in high-risk head and neck cancer by modulating autophagy. Adv Cancer Biol-Metastasis. 2023;7:100085. doi: 10.1016/j.adcanc.2022.100085.
  13. Chandrashekar DS, Karthikeyan SK, Korla PK, Patel H, Shovon AR, Athar M, et al. UALCAN: An update to the integrated cancer data analysis platform. Neoplasia. 2022;25:18–27. doi: 10.1016/j.neo.2022.01.001. PMID: 35078134; PMCID: PMC8788199.
  14. Wong NW, Chen Y, Chen S, Wang X. OncomiR: an online resource for exploring pan-cancer microRNA dysregulation. Bioinformatics. 2018;34(4):713-5. doi: 10.1093/bioinformatics/btx627. PMID: 29028907; PMCID: PMC5860608.
  15. Li JH, Liu S, Zhou H, Qu LH, Yang JH. starBase v2.0: decoding miRNA-ceRNA, miRNA-ncRNA and protein–RNA interaction networks from large-scale CLIP-Seq data. Nucleic Acids Res. 2014;42(D1):D92–D97. doi: 10.1093/nar/gkt1248. PMID: 24297251; PMCID: PMC3964941.
  16. Mi H, Muruganujan A, Huang X, Ebert D, Mills C, Guo X, Thomas PD. Protocol update for large-scale genome and gene function analysis with the PANTHER classification system (v.14.0). Nat Protoc. 2019;14(3):703-21. doi: 10.1038/s41596-019-0128-8. PMID: 30804569; PMCID: PMC6519457.
  17. Liang M, Zhang C, Yang Y, Cui Q, Zhang J, Cui C. TransmiR v3.0: an updated transcription factor-microRNA regulation database. Nucleic Acids Res. 2025;53(D1):D318-D323. doi: 10.1093/nar/gkae1081. PMID: 39530226; PMCID: PMC11701595.
  18. Posta M, Győrffy B. Pathway-level mutational signatures predict breast cancer outcomes and reveal therapeutic targets. Br J Pharmacol. 2025;182(23):5734-47. doi: 10.1111/bph.70215. PMID: 41057034.
  19. Quan Y, Huang X, Quan X. Expression of miRNA-206 and miRNA-145 in breast cancer and correlation with prognosis. Oncol Lett. 2018;16(5):6638-42. doi: 10.3892/ol.2018.9440. PMID: 30405803; PMCID: PMC6202535.
  20. Petrović N, Todorović L, Nedeljković M, Božović A, Bukumirić Z, Tanić ND, et al. Dual function miR-205 is positively associated with ER and negatively with five-year survival in breast cancer patients. Pathol Res Pract. 2022;238:154080. doi: 10.1016/j.prp.2022.154080. PMID: 35994808.
  21. Chirshev E, Oberg KC, Ioffe YJ, Unternaehrer JJ. Let-7 as biomarker, prognostic indicator, and therapy for precision medicine in cancer. Clin Trans med. 2019;8(1):24. doi: 10.1186/s40169-019-0240-y. PMID: 31468250; PMCID: PMC6715759.
  22. Sun H, Dai J, Chen M, Chen Q, Xie Q, Zhang W, et al. miR-139-5p was identified as biomarker of different molecular subtypes of breast carcinoma. Front Oncol. 2022;12:857714. doi: 10.3389/fonc.2022.857714. PMID: 35433464; PMCID: PMC9009410.
  23. Syed RU, Banu H, Alshammrani A, Alshammari MD, Kadimpati KK, Khalifa AAS, et al. MicroRNA-21 (miR-21) in breast cancer: From apoptosis dysregulation to therapeutic opportunities. Pathol Res Pract. 2024;262:155572. doi: 10.1016/j.prp.2024.155572. PMID: 39226804.
  24. Di Martino MT, Arbitrio M, Caracciolo D, Cordua A, Cuomo O, Grillone K, et al. miR-221/222 as biomarkers and targets for therapeutic intervention on cancer and other diseases: A systematic review. Mol Ther Nucleic Acids. 2022;27:1191-224. doi: 10.1016/j.omtn.2022.02.005. PMID: 35282417; PMCID: PMC8891816
  25. Akrida I, Makrygianni M, Nikou S, Mulita F, Bravou V, Papadaki H. Hippo pathway effectors YAP, TAZ and TEAD are associated with EMT master regulators ZEB, Snail and with aggressive phenotype in phyllodes breast tumors. Pathol Res Pract. 2024;262:155551. doi: 10.1016/j.prp.2024.155551. PMID: 39153238.
  26. González-Alonso P, Zazo S, Martín-Aparicio E, Luque M, Chamizo C, Sanz-Álvarez M, et al. The hippo pathway transducers YAP1/TEAD induce acquired resistance to trastuzumab in HER2-positive breast cancer. Cancers. 2020;12(5):1108. doi: 10.3390/cancers12051108. PMID: 32365528; PMCID: PMC7281325.
  27. Yu M, Chen Y, Li X, Yang R, Zhang L, Huangfu L, et al. YAP1 contributes to NSCLC invasion and migration by promoting SLUG transcription via the transcription co-factor TEAD. Cell Death Dis. 2018;9(5):464. doi: 10.1038/s41419-018-0515-z. PMID: 29700328; PMCID: PMC5920099.
  28. Leeksma AC, Derks IA, Garrick B, Jongejan A, Colombo M, Bloedjes T, et al. SMG1, a nonsense-mediated mRNA decay (NMD) regulator, as a candidate therapeutic target in multiple myeloma. Mol Oncol. 2023;17(2):284-97. doi: 10.1002/1878-0261.13343. PMID: 36400430; PMCID: PMC9892823.
  29. Kim M, Hong WC, Kang HW, Kim JH, Lee D, Cheong JH, et al. SLC5A3 depletion promotes apoptosis by inducing mitochondrial dysfunction and mitophagy in gemcitabine-resistant pancreatic cancer cells. Cell Death Dis. 2025;16(1):161. doi: 10.1038/s41419-025-07476-5. PMID: 40055335; PMCID: PMC11889219.
  30. Chen Y, Wang W, Fang L, Zhang Z, Deng S. Identification of PTK2 as an adverse prognostic biomarker in breast cancer by integrated bioinformatics and experimental analyses. Front Mol Biosci. 2022;9:984564. doi: 10.3389/fmolb.2022.984564. PMID: 36533074; PMCID: PMC9751198.
  31. Kristensen LS, Jakobsen T, Hager H, Kjems J. The emerging roles of circRNAs in cancer and oncology. Nat Rev Clin Oncol. 2022;19(3):188-206. doi: 10.1038/s41571-021-00585-y. PMID: 34912049.
  32. Chen S, Li X, Guo L, Zhang J, Li L, Wang X, et al. Characterization of the m6A-related lncRNA signature in predicting prognosis and immune response in patients with colon cancer. J BUON. 2021;26(5):1931-41. PMID: 34761602.
  33. Ren H, Shen X, Xie M, Guo X. Construction of a prognostic score model for breast cancer based on multi-omics analysis of study on bone metastasis. Transl Cancer Res. 2024;13(5):2419-36. doi: 10.21037/tcr-23-1881. PMID: 38881940; PMCID: PMC11170530.
  34. Singh S, Sinha T, Panda AC. Regulation of microRNA by circular RNA. Wiley Interdiscip Rev RNA. 2024;15(1):e1820. doi.org/10.1002/wrna.1820.
Middle East Journal of Cancer

Articles in Press, Accepted Manuscript
Available Online from 01 January 2027
Files
Share
How to cite
Statistics